Washington [US], November 21 (ANI): Each individual has an individual chemical fingerprint. The composition of small molecules in the blood, such as fats or sugars, determines how our body reacts to external influences, which diseases we are susceptible to and how severe an illness will be.
In an international collaboration with partners from Cambridge (UK), scientists from the Berlin Institute of Health at the Charite (BIH) have now discovered more than 300 regions in the genome that contribute to this individual chemical fingerprint. They have now published their results in Nature Medicine.
So Read| Sumbul Ne Liya Khudka Stand, Kya Yehi Hai Unke Aur Shalin Ke Dosti Ka the End? … – Latest Tweet by ColorsTV.
Our body continuously processes thousands of small molecules to maintain our metabolism, and thus our health. Even small changes can cause illness and metabolism is as individual as the person. Scientists at BIH have now discovered rare and common changes in the genetic code that influence the personal chemical fingerprint and the individual disease profile.
“With our study, we are finally illuminating the genetic control of our metabolism based on many hundreds of small metabolites, which has never been shown in such detail,” says Professor Claudia Langenberg, Head of the Computational Medicine Department, adding: “This means we now better understand how and why genetic differences contribute to the development of diseases.”
So Read| Andhra Pradesh: Prakasam District Police Rescue 36 Donkeys From Slaughter, Over 500kg Donkey Meat Seized.
Blood samples from 20,000 participants
The scientists measured the number of small molecules, such as sugars, fats, or hormones, from blood samples of about 20,000 participants in two large population studies to investigate the influence of the genome. They identified regions in the genome that are linked to many, often very different, metabolites.
“These metabolic ‘hotspots’ in the genome have helped us to better understand which genes are relevant to the changing amounts of molecules in the blood,” explains Professor Claudia Langenberg. “With these new findings, we were then able to show which changes in metabolism contribute to the development of individual diseases, such as breast cancer,” she adds.
Metabolism also determines drug effects
The results show that metabolism not only contributes to maintaining health or allowing diseases to develop but also significantly determines how effective or sometimes harmful drugs work. For example, the scientists found common variation in the genetic code close to the DPYD gene in about one-fifth of the study participants.
DPYD encodes for the product, called an enzyme, that is responsible to break down certain cancer drugs and people harboring those genetic variants are at an increased risk to accumulate toxic levels in the blood. This means that genetic testing can tailor treatment decisions.
“Variations near genes that are also the target of drugs can give us clues about possible unwanted side effects. For example, we were able to show that drugs that reduce the conversion of steroid hormones in the body and thus counteract male hair loss and a prostate enlargement may increase the risk of depression, which is consistent with reports from drug studies,” she explains.
The scientists have also identified many examples of the influence of metabolites on various diseases, including an increased blood concentration of homoarginine that increases the risk of chronic renal failure. This is relevant because the administration of homoarginine is currently being tested for the prevention of cardiovascular disease. In these people, special attention should therefore be paid to maintaining kidney function.
International cooperation makes research possible
The study is the result of many years of cooperation between BIH scientists and colleagues from all over the world, especially from the Medical Research Council (MRC) Epidemiology Unit at the University of Cambridge. Many experts have worked together to better understand and assign the biological relevance and causal genes of the results, including from the Helmholtz Center in Munich, Qatar and the pharmaceutical company Pfizer.
Already, Claudia Langenberg is leading a new initiative. “We need larger studies that better map the genetic diversity of different populations to understand the biological and clinical effect of genetic variations that differ between certain populations.” (ANI)
(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)